Viking Therapeutics
VKTX

Viking Therapeutics (VKTX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
JP MorganMaintainedOverweight$65.00 from $75.00Aug 11, 2026
Canaccord GenuityMaintainedBuy$114.00 from $107.00Jul 30, 2026
Lake StreetInitiated CoverageBuy$89.00May 28, 2026
BTIGMaintainedBuy$125.00May 1, 2026
Cantor FitzgeraldMaintainedOverweight$100.00 from $105.00Apr 30, 2026
HC Wainwright & Co.MaintainedBuy$102.00Mar 23, 2026
Canaccord GenuityMaintainedBuy$107.00 from $106.00Nov 12, 2025
Canaccord GenuityInitiated CoverageBuy$106.00Oct 29, 2025
JP MorganMaintainedOverweight$75.00 from $80.00Oct 24, 2025
Morgan StanleyMaintainedOverweight$102.00 from $98.00Oct 23, 2025
HC Wainwright & Co.MaintainedBuy$102.00Sep 29, 2025
BTIGMaintainedBuy$125.00Sep 22, 2025
HC Wainwright & Co.MaintainedBuy$102.00Aug 19, 2025
CitigroupMaintainedNeutral$38.00 from $31.00Jul 24, 2025
Raymond JamesMaintainedStrong Buy$122.00 from $125.00Jul 24, 2025
HC Wainwright & Co.MaintainedBuy$102.00Jun 25, 2025
Truist SecuritiesMaintainedBuy$75.00 from $95.00Apr 28, 2025
Cantor FitzgeraldInitiated CoverageOverweight$104.00Apr 28, 2025
HC Wainwright & Co.MaintainedBuy$102.00Apr 24, 2025
Morgan StanleyMaintainedOverweight$102.00 from $105.00Apr 24, 2025

Frequently asked questions

  • What is the latest analyst rating on VKTX?

    On Aug 11, 2026, JP Morgan maintained Viking Therapeutics at Overweight with a price target of $65.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.